Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

Autor: A. Del Conte, Fabrizio Tabbò, Emilio Bria, Sara Pilotto, Evaristo Maiello, Domenico Galetta, F.L. Cecere, Rita Chiari, Concetta Sergi, Frederico Cappuzzo, P. Pizzutillo, F. Riccardi, Marcello Tiseo, G. Borra, Vieri Scotti, Paola Bordi, Olga Martelli, Claudia Bareggi, Giulio Rossi, L. Ghilardi, Paolo Graziano, C. Casartelli, Elisa Gobbini, P. Rizzo, Antonio Rossi, M. Di Maio, Vanesa Gregorc, Angelo Delmonte, G. Osman, Diego Cortinovis, Silvia Novello
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
ALK inhibitors
Male
Cancer Research
Lung Neoplasms
non-small cell lung cancer (NSCLC)
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
80 and over
Anaplastic lymphoma kinase
Anaplastic Lymphoma Kinase
Non-Small-Cell Lung
Aged
80 and over
Gene Rearrangement
education.field_of_study
General Medicine
Middle Aged
Treatment Outcome
Italy
030220 oncology & carcinogenesis
Female
Lung cancer
medicine.drug
Adult
medicine.medical_specialty
Brigatinib
Population
03 medical and health sciences
Young Adult
Crizotinib
Internal medicine
Sequence
medicine
Humans
education
Protein Kinase Inhibitors
Aged
Retrospective Studies
business.industry
Carcinoma
Gene rearrangement
medicine.disease
Lorlatinib
030104 developmental biology
business
Zdroj: Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22(3)
ISSN: 1699-3055
Popis: Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9–11.2] and 11.1 months [CI 95% 9.2–13.8], respectively, while TTF were 10.2 [CI 95% 8.5–12.6] and 11.9 months [CI 95% 9.7–17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3–33.7] in PFS and 30.4 months [CI 95% 24.7–34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8–54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0–73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6–NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3–34.0)] (P
Databáze: OpenAIRE
Externí odkaz: